Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019
Cyclacel Pharmaceuticals, Inc. (CYCC)
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cyclacel.com/investor-relations
Company Research
Source: GlobeNewswire
BERKELEY HEIGHTS, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2018 achievements and providing an outline of the Company’s key business objectives for 2019. Cyclacel’s clinical and business strategy will be highlighted at a presentation during the 2019 Biotech Showcase Conference on Tuesday, January 8, 2019 from 9:30 a.m. – 10:00 a.m. PST in the Yosemite C Suite at the Hilton San Francisco Union Square. "In 2018, we presented our targeted oncology strategy with the objective of delivering important data readouts in the next twelve months,” said Spiro Rombotis, President and Chief Executive Officer. “At the heart of our business strategy is targeting cancer patients with overexpression of resistance pathways, including Mcl-1, and inherited mutations in DNA damage pat
Show less
Read more
Impact Snapshot
Event Time:
CYCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYCC alerts
High impacting Cyclacel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CYCC
News
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerGlobeNewswire
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
CYCC
Earnings
- 3/19/24 - Beat
CYCC
Sec Filings
- 4/19/24 - Form S-1/A
- 3/28/24 - Form 8-K
- 3/25/24 - Form S-1
- CYCC's page on the SEC website